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ABSTRACT  45 
 46 
Purpose: To predict risk of local recurrence (LR) in ductal carcinoma in situ (DCIS) with a new 47 
visualization and quantification approach using centrosome amplification (CA), a cancer-cell specific 48 
trait, widely associated with aggressiveness.  49 
 50 
Experimental Design: This first-of-its-kind methodology evaluates the severity and frequency of 51 
numerical and structural CA present within DCIS, and assigns a quantitative centrosomal amplification 52 
score (CAS) to each sample. Analyses were performed in a discovery cohort (DC, n=133) and a 53 
validation cohort (VC, n=119). 54 
 55 
Results: DCIS cases with LR exhibited significantly higher CAS than recurrence-free cases. Higher 56 
CAS was associated with a greater risk of developing LR (HR=6.3 and 4.8 for DC and VC, respectively; 57 
p<0.001). CAS remained an independent predictor of relapse-free survival (HR=7.4 and 4.5 for DC and 58 
VC, respectively; p<0.001) even after accounting for potentially confounding factors (grade, age, 59 
comedo necrosis and radiotherapy). Patient stratification using CAS (p<0.0001) was superior to that by 60 
Van Nuys Prognostic Index (VNPI) (HR for CAS=6.2, vs. HR for VNPI=1.1). Among patients treated 61 
with breast-conserving surgery alone, CAS identified patients likely to benefit from adjuvant 62 
radiotherapy (RT). 63 
 64 
Conclusions: CAS predicted 10-year LR risk for patients who underwent surgical management alone 65 
and identified patients who may be at low risk of recurrence, and for whom adjuvant RT may not be 66 
required. CAS demonstrated the highest concordance among the known prognostic models such as 67 
VNPI and clinicopathological variables such as grade, age, and comedo necrosis.  68 
 69 
Translational Relevance: This is the first study to quantitate amplified centrosomes using a semi-70 
automated pipeline technology that integrates immunofluorescence confocal microscopy with digital 71 
image analysis to generate a quantitative centrosome amplification score (CAS). CAS is a summation 72 
of the severity and frequency of centrosomal aberrations in clinical tumor samples. Our study 73 
represents the first step in developing CAS as a readily quantifiable biomarker that can predict the risk 74 
of local recurrence (LR) in DCIS with higher concordance than existing predictive tools. CAS stratifies 75 
lumpectomy cases into “low-CA DCIS” and “high-CA DCIS” wherein “high-CA DCIS” are much more 76 
likely to have LR, thereby aiding treatment decision-making. This study is also the first to highlight 77 
organellar-level differences between recurrent and non-recurrent DCIS. CAS may serve as a promising 78 













Approximately 20% of screen-detected breast cancers (BC) are DCIS, a pre-invasive form of BC 91 
wherein malignant epithelial cells are confined to the lumen of a mammary duct and do not invade into 92 
the adjacent stroma (1,2). Notably, 20-53% of women with untreated DCIS progress to invasive BC 93 
over a period of ≥10 years (3). Since the progressive potential of a DCIS lesion cannot be reliably 94 
determined, local control via surgical excision with or without local radiotherapy is the mainstay 95 
strategy, with addition of endocrine blockade in some cases (4). Unfortunately, 10-35% of DCIS 96 
patients treated with lumpectomy or breast conservation surgery (BCS) later present with a local 97 
recurrence (LR) and about half of all recurrences occur in the form of invasive breast cancer (IBC) 98 
(5,6). A major challenge is to avoid under- or over-treatment by developing prognostic biomarkers that 99 
can stratify DCIS patients based on their recurrence risk. 100 
 101 
Current predictors of recurrence risk for DCIS such as the Van Nuys Prognostic Index (VNPI) (7) and 102 
the Memorial Sloan Kettering DCIS nomogram (8) are based on routinely-used clinicopathological 103 
parameters but lack consistency and reproducibility in risk prediction (9,10). In addition, these tools do 104 
not integrate prognostically-informative molecular predictors, and underestimate DCIS heterogeneity. 105 
While Oncotype Dx Breast DCIS score, a commercially-available gene-expression based assay, has 106 
some value in predicting LR, it has only been validated in two cohorts (ECOG E5194 and Ontario 107 
DCIS). The poor stratification of high/intermediate-risk patients in these two cohorts has called into 108 
question the prognostic value of this tool (11).  109 
 110 
Extensive genetic and phenotypic intratumoral heterogeneity (ITH) characterizes DCIS (12,13). In a 111 
pre-invasive lesion, higher ITH predicts greater likelihood of LR and invasive BC (14). Amplified 112 
centrosomes underlie erroneous mitoses and fuel chromosomal instability (CIN), which is a well-113 
recognized driver of ITH (15,16). Although normal cells have one centrosome pre- S-phase and two 114 
centrosomes post- S-phase, cancer cells invariably display centrosome amplification (CA); an abnormal 115 
increase in the number (i.e., numerical amplification) and/or volume (i.e., structural amplification) of 116 
centrosomes (17). Semi-quantitative studies have shown that CA correlates with higher tumor grade, 117 
larger tumor size, disease recurrence and/or distant metastasis in various malignancies (18). Moreover, 118 
CA occurs within precancerous and preinvasive lesions including DCIS, suggesting that CA is an early 119 
event in tumorigenesis (19,20). CA increases with higher DCIS grade, and high-grade (HG) DCIS has 120 
elevated expression of Aurora-A and Nek2 kinases that are strongly associated with CA. In addition, 121 
the risk of LR in DCIS is predictable by dysregulation of genes like cyclin-D, cyclin-E, and p53/p21 that 122 
regulate the centrosome duplication process (21). In the present study, we postulated that recurrent 123 
and non-recurrent DCIS cases might differ in the extent and/or type of CA. The prognostic value of CA 124 
has remained unexplored for clinical application, as there is no methodology available for the rigorous 125 
quantitation of CA phenotypes. Also, it is unclear whether the prognostic value of CA lies in numerical 126 
and/or structural CA. It is unknown which of the two features of CA--frequency (i.e., percentage of cells 127 
showing amplified centrosomes), and/or severity (i.e., how abnormal the number/volume of 128 
centrosomes is in a given sample) --is prognostically informative.  129 
 130 
Herein, we present a new methodology for centrosomal phenotyping to quantitate both numerical and 131 
structural centrosomal aberrations in clinical tissue samples. Centrosomes were immunofluorescently 132 
4 
stained using an antibody against γ-tubulin, and co-stained nuclei with Hoechst. Our analytical 133 
procedure allows robust interrogation of the capacity of centrosomal overload to predict the risk of LR 134 
after a lumpectomy. We have developed an algorithm that quantitates the frequency/prevalence and 135 
severity of CA (both numerical and structural) in formalin-fixed paraffin-embedded (FFPE) clinical 136 
samples, and computes a centrosome amplification score (CAS) for each sample. CAS is a promising 137 
metric that may improve treatment recommendations and allow identification of patients at low risk of 138 
recurrence for whom adjuvant RT may not be required. CAS demonstrates the highest concordance 139 
among the known prognostic models such as VNPI and commonly used clinicopathological variables 140 
such as grade, age, and comedo necrosis. 141 
 142 
Materials and Methods 143 
 144 
Clinical tissue samples 145 
 146 
This is a retrospective study included FFPE tissue sections of primary pure DCIS consecutively 147 
diagnosed between 1988 and 2012 were obtained from Nottingham City Hospital, UK. Tumor tissue 148 
were preserved by standard approved processing methods using formalin fixation and embedding  in 149 
paraffin. These tumor blocks were stored in the Nottingham tissue bank. Patients had (a) adequate 150 
amount of tissue, (b) available all relevant clinicopathologic data, and (c) at least 10 years of follow-up 151 
were eventually included in the study. The samples for the study were shared in three batches. For the 152 
pilot study to estimate the sample size, samples for the first 50 consecutive cases that met inclusion 153 
criteria were shared and based upon our findings, the proposed sample size of 116 for each cohort was 154 
expected to yield a power of 80% with an alpha of 0.05 (Supplementary Fig. 1). Subsequently, samples 155 
for the next 83 cases were shared which together with the earlier 50 samples formed the discovery 156 
cohort (DC). The validation cohort (VC) was received only after the study (staining, imaging, and image 157 
analysis) on the DC was completed. To exclude any bias, the GSU research group were totally blinded 158 
to clinicopathologic and outcome details of the patients included in the study. These data were not 159 
shared with GSU research team who performed the staining, imaging, and image analysis until the 160 
CAS scores were generated for each patient in all cohorts. The discovery cohort (DC) (n=133) and 161 
validation cohort (VC) (N=119) comprised of consecutive pure DCIS patients (no evidence of 162 
microinvasive or invasive breast cancer) with available tissue samples that showed free surgical 163 
margins >2mm (to avoid the effect of this confounder on the study outcome) and underwent BCS or 164 
mastectomy with or without adjuvant radiotherapy (RT) (Supplementary Fig. 2) (22-24). All cases were 165 
histologically reviewed, and diagnoses were confirmed by two independent pathologists (MST and IM, 166 
and in case of disagreement between the two reviewing pathologists the specialist breast pathologist 167 
(EAR) confirmed the diagnosis). All cases included data pertaining to their clinicopathologic variables 168 
such as age at diagnosis, menopausal status, DCIS size, nuclear grade, presence of comedo-type 169 
necrosis, treatment, VNPI, Ki67 proliferation index, and information about treatment (adjuvant RT), 170 
recurrence-free survival (RFS) defined by the time (in months) between 6 months after the first surgery 171 
and occurrence of ipsilateral LR in the form of either DCIS or IBC, date of initial diagnosis, date of 172 
surgery, and patient status at last contact (23). Patients who underwent completion surgery within the 173 
first 6 months after primary resection surgery due to positive/close surgical margins or presence of 174 
residual tumor tissue were not considered to have disease recurrence. All patients who developed 175 
contralateral breast events were censored at the time of development of the contralateral tumor. None 176 
of the patients in our discovery/validation cohorts received adjuvant endocrine therapy. 177 
To determine normal volumes of the centrosomes, full-face sections of normal breast tissue from 178 
reduction mammoplasties (n=40) and breast tumors with extensive regions of adjacent uninvolved 179 
tissues (n=40) were obtained from Stavanger University Hospital, Norway, Nottingham City Hospital, 180 
5 
UK, and West Georgia Hospital, GA, USA. All study aspects were (a) approved by every Institutional 181 
Review Board, and (b) in compliance with guidelines in material transfer and data use agreements for 182 
all involved institutions, and Georgia State University. Informed consent was obtained from all subjects. 183 
 184 
Immunofluorescence staining and confocal microscopy imaging of clinical samples 185 
 186 
Centrosomes were immunofluorescently stained for γ-tubulin (red) and nuclei (with Hoechst) in paraffin-187 
embedded sections of DCIS. Images of tissue samples were acquired with a Zeiss LSM 700 confocal 188 
microscope (using 63x oil immersion lens with a numerical aperture of 1.4 at 1.5x optical zoom). All 189 
imaging parameters were fixed across all samples. For optimal results, laser power was adjusted to the 190 
minimum level wherein fluorophore emission was saturated. For detector saturation, the gain (master) 191 
was adjusted such that the detector registers the target fluorophores in each channel within full range of 192 
detector settings (8-bit, 12-bit, 16-bit) to prevent over- and under-saturation and maximize accuracy. 193 
The offset was adjusted to minimize the background in the sample. Normal, DCIS and IBC areas pre-194 
marked by a pathologist were imaged to obtain at least 10 regions of interest (ROIs) each containing 195 
20-30 nuclei and associated centrosomes (Fig. 1).   196 
 197 
 198 
Scoring of centrosomes in clinical samples 199 
 200 
Raw 3D image data were processed using IMARIS Biplane 8.2 3D volume rendering software to 201 
determine the volume of each centrosome within each ROI. “Volume rendering” refers to transforming a 202 
2D image stack for 3D visualization and subsequent analysis. To exclude non-specific signals, a 203 
common background subtraction was applied to all images. This parameter was derived by first 204 
measuring the average diameter of ~100 centrosomes in 10 ROIs (Fig. 1), and then using the 205 
background corresponding to this average diameter as the background subtraction threshold. Finally, 206 
data from all optical sections were ordered to enable volume measurement for each centrosome. The 207 
final data of volumes of all centrosomes were then compared to a maximum intensity projection image 208 
and centrosomes for each cell were quantified based on proximity to their associated nuclei. The 209 
number and volume of all centrosomes associated with each nucleus in the tumor area were recorded.    210 
Categorization of centrosomes into iCTRs and mCTRs  211 
 212 
Centrosomes in breast tissue (normal, DCIS or IBC) were categorized into individually distinguishable 213 
centrosomes (iCTRs) and megacentrosomes (mCTRs). iCTRs were defined as centrosomes that stain 214 
positive for γ-tubulin; iCTR numbers and boundaries were clearly distinguishable, and their volumes lay 215 
within the range of centrosome volumes found in normal breast tissue stained for γ-tubulin. The volume 216 
range for a normal centrosome was determined by analyzing volumes of centrosomes from both 217 
adjacent uninvolved tissue from cancer patients and normal breast tissue from disease-free individuals 218 
(Supplementary Fig. 3). For adjacent uninvolved tissues, the selected cohort (n=40 patients) had a 219 
median age of 53.5 years (age range: 38–69.5 years). We evaluated centrosomal volumes in these 220 
samples as described in the analysis section. The mean centrosome volume for the adjacent 221 
uninvolved tissue sections was higher relative to the normal tissue from reduction mammoplasty. Thus, 222 
we chose the smallest and largest values for individual centrosome volume from normal tissue as the 223 
6 
“normal centrosome volume range” for breast tissue. The mean volume of centrosomes in normal 224 
breast epithelial cells ranged from 0.2-0.74 µm3. Centrosomes with volumes > 0.74 µm3 were 225 
categorized as mCTRs. All centrosomes in each ROI were thus categorized as iCTRs or mCTRs. In 226 
other words, mCTRs are centrosomes with aberrantly large volumes and are considered to represent 227 
structurally amplified centrosomes. The numbers and volumes of each iCTR and mCTR associated 228 
with each nucleus in an ROI were recorded. 229 
 230 
Algorithm-based analytics 231 
 232 
For each sample, a cumulative CAS (CAStotal) was computed based on the formula:  CAStotal =CASi 233 
+ CASm, where CASi and CASm are scores that describe numerical and structural CA phenotypes, 234 
respectively. Details on quantitation of numerical and structural CA are added in Supplementary data. 235 
 236 
Statistical Analysis 237 
 238 
Statistical analysis was accomplished with SAS 9.4 software (Cary, NC, USA), and the R-project 239 
version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria, https://www.R-project.org/). Raw 240 
CA volume data were converted to CASi, CASm and CAStotal according to the  algorithm. Scaling 241 
factors recommended were used to normalize score of CASi and CASm in the range 0–3. Chi-square 242 
tests were performed to check recurrence proportions in patient subgroups. The tests of group mean 243 
differences shown in Box Plots were based on nonparametric Wilcoxon Rank Sum Tests and Kruskal-244 
Wallis tests depending on the number of groups used for comparison, where the y-axis reflects the 245 
ranks of observations. RFS was used as the endpoint for the survival analysis (restricted to 10 years). 246 
The optimal cutoff (threshold used to categorize patients into high-or low-risk of LR subgroups) of the 247 
CAStotal value was selected based on the results of 133 log-rank tests. We simply set each possible 248 
CAStotal value from 133 cases in the DC as cutoff and then constructed Kaplan-Meier survival 249 
estimators for cases classified into high-risk and low-risk groups. The value 1.436 was finalized since it 250 
minimized the log-rank p-value. The same CAStotal cutoff was then used for the 119 cases from the 251 
VC to validate the model’s effectiveness. Both univariate and multivariable Cox proportional hazard 252 
models, with age, grade, comedo necrosis, and RT controlled, were built to estimate Hazard Ratios 253 
(HRs) and 95% confidence intervals (CIs) between high vs. low CAStotal groups. A non-zero slope was 254 
detected in a generalized linear regression of the scaled Schoenfeld residuals on functions of time, 255 
which satisfied of the proportional hazards assumption (Supplementary Fig. 5). A 2X2 confusion matrix 256 
and performance metrics was used for sensitivity analysis. The fitted Cox models were also used to 257 
predict the approximate 10-year recurrence rate using SAS PROC PHREG module. For all tests p<0.05 258 





Traditional clinicopathological variables have limited capacity to predict recurrence for DCIS 264 
patients  265 
 266 
7 
We found that among the 133 patients in the DC (details in Table 1), 28 patients developed ipsilateral 267 
LR. The median age at diagnosis was 58 years (age range: 41–84), and median follow-up was 132 268 
months (14-333 months). Out of 133 patients, ~42% (n=55) received RT. Higher nuclear grade, the 269 
presence of comedo necrosis and the use of RT were clinicopathological parameters that showed 270 
proportional differences between recurring and LR-free patient subgroups (Table 1A). However, only 271 
high grade and comedo necrosis showed associations with RFS in a univariable Cox regression 272 
analysis (Table 2A). Intriguingly, none of these clinicopathological variables showed any significant 273 
association with RFS in multivariate analyses (Table 2A), thereby indicating the limited capacity of 274 
traditional clinicopathological variables to predict LR for DCIS in our DC. Our VC was also from 275 
Nottingham University Hospital, UK (patient characteristics in Table 1B) and comprised of 119 DCIS 276 
patients out of which 24 patients presented with ipsilateral LR. Median age of these patients was 56 277 
years, and the median follow-up was 121 months. Histograms representing distribution of age and 278 
tumor size are added in the supplementary data (Supplementary Fig. 6). In addition we performed the 279 
KM survival analysis to show the effect of standard prognostic markers like age, tumor size, 280 
radiotherapy and comedo necrosis on recurrence for the whole dataset (DC and VC, n=252) 281 
(Supplementary Fig. 7). Out of 119 patients, ~12% (n=14) received RT. In the VC, tumor size, 282 
presence of the comedo necrosis, and age, showed significant proportional differences between the 283 
LR and LR-free subgroups.  284 
 285 
Recurrent DCIS patients show higher CAS compared to non-recurrent DCIS ones 286 
 287 
Centrosome numbers and volumes, evaluated and scored for numerical (CASi) and structural (CASm) 288 
centrosomal aberrations (as described in methods) were integrated using our algorithm to generate a 289 
composite CAStotal value for each sample of the DC (Fig 2A, B). Interestingly, DCIS patients that 290 
developed LR within 10 years showed significantly higher CASi relative to LR-free patients (p=<0.0001; 291 
Fig. 2C). These patients with LR showed greater severity (CASi severity) (p=0.25; Supplementary Fig. 292 
8A) and higher frequency (CASi frequency) (p<0.0001; Supplementary Fig. 8B) of numerical CA 293 
compared to LR-free patients. Analysis of structural CA revealed that CASm was significantly higher 294 
(p=0.04, Fig. 2D) for the LR subgroup relative to LR-free subgroup. DCIS with LR exhibited greater 295 
severity (CASm severity) (p=0.01, Supplementary Fig. 8C) and frequency (CASm frequency) (p=0.08, 296 
Supplementary Fig. 8D) of structural CA compared to LR-free DCIS. Cumulatively, a summation of 297 
CASi and CASm generated CAStotal, which was significantly higher for DCIS patients with LR relative 298 
to LR-free patients regardless of grade (mean scores in Supplementary Table 1) (Fig. 2E).  299 
 300 
Employing the same methodology for the VC, we calculated CAS (Supplementary Fig. 9) and found 301 
that irrespective of grade, DCIS cases with LR exhibited higher CAStotal relative to LR-free patients 302 
(p<0.0001) (Fig. 2F). Further, similar trends were seen for other CAS subcomponents as observed in 303 
the DC; the  ranked mean values of CASi (p<0.0001) (Fig. 2G) and CASm (p<0.0001) (Fig. 2H), 304 
including their severity (CASi severity p=0.0014; CASm severity  p=0.014) and frequency (CASi 305 
frequency p<0.0001, CASm frequency p<0.0001) components, were higher in the patient subgroup with 306 
LR than in the LR-free subgroup (Supplementary Fig. 8 E, F,G,H). 307 
 308 
Similar findings were evident for grade-matched patients in DC and VC (Supplementary Fig. 10) and 309 
patients that were treated only with BCS (Supplementary Fig. 11). Collectively, our data strongly 310 
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suggest a stark difference in centrosomal aberrations between DCIS tumors of patients with and 311 
without LR. 312 
 313 
Next, we co-immunolabeled 15 high-grade DCIS samples for both centrosomes (using anti γ-tubulin 314 
antibody) and centrioles (using anti-centrin-2 antibody) and generated CAStotal as described before. In 315 
all samples, γ-tubulin foci invariably overlapped with centrin-2 foci, confirming that both structurally and 316 
numerically amplified centrosomes are bona fide centrosomes and not simply aggregates of 317 
pericentriolar material. We also observed that none of the mCTRs had >2 centrin-2 foci, suggesting that 318 
enlarged γ-tubulin foci represent structurally augmented centrosomes and not supernumerary 319 
centrosomes that are tightly clustered to be indistinguishable (Supplementary Fig. 12). 320 
 321 
CAS stratifies DCIS patients into subgroups with high- and low- risk of LR within 10 years of 322 
diagnosis 323 
 324 
Upon stratification of all DC patients into low- and high-CAS groups (the threshold used was the one 325 
that minimized log-rank p-value) (Fig. 3), we found that DCIS patients with high CASi were associated 326 
with poorer RFS (p<0.001, HR=4.80) relative to those with low CASi (Fig. 3A, Supplementary Fig. 13A, 327 
B, and Supplementary Table 2). Similarly, high CASm was associated with poorer RFS (p=0.04, 328 
HR=2.396) compared to low CASm (Fig. 3B, Supplementary Fig. 13C, 13D, and Supplementary Table 329 
2). CAStotal stratified the high-risk and low-risk DCIS patients with high significance and hazard ratio 330 
(p<0.001, HR= 6.3) (Fig. 3C). We found that 85.7% of patients with LR were in the high CAStotal group. 331 
This association with CAStotal remained significant (p<0.001, HR=7.4) even after accounting for 332 
potential confounders, including comedo necrosis, tumor grade, age, RT, and receptor status (Table 333 
2A). Although presence of comedo necrosis and CAStotal were associated with RFS in univariate 334 
analyses, only CAStotal remained significantly associated with RFS in multivariable analyses (Table 335 
2A). Furthermore, when similar cox regression univariate and multivariate analysis was performed for 336 
CASi and CASm separately CASi and CASm was the strongest and most significant independent 337 
predictor of RFS respectively (Supplementary Table 3A and 4A) Similar results were evident for the 338 
cases that were treated only with lumpectomy (Supplementary Fig. 14).  339 
 340 
To verify whether CAStotal, CASi, and CASm could be used to stratify patients in the VC, we used pre-341 
determined CAS cutoffs from the DC (Fig. 3). We found that high CASi, CASm and CAStotal were 342 
associated with poorer RFS compared to low CASi, CASm and CAStotal, respectively. Of the patients 343 
with LR, 75% were classified into the high CASi group (Fig. 3D) and ~67% of patients with LR were 344 
classified into the high CAStotal subgroups (Fig. 3E). Of the patients in the recurrence-free group, 87% 345 
were classified in the low CASm group (Fig. 3F). In both univariate and multivariate analyses after 346 
adjusting for potentially confounding effects of factors like age, grade, RT and receptor status CAStotal 347 
and comedo necrosis was the strongest and most significant independent predictor of RFS (i.e., HRs 348 
for CAStotal were higher than HRs of all other clinicopathologic factors (Table 2B). Similar to DC we 349 
observed that CASi and CASm also independently predicted the RFS (Supplementary Table 3B and 350 
4B).  351 
 352 
In addition we performed the bootstrap analysis for the COX regression univariate and multivariate 353 
models on the combined (DC+VC=252) dataset and observed that mean HR for the univariate analysis 354 
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is 5.22 and the multivariate analysis conditional on all other variables is 6.58 (p <0.0001) 355 
(Supplementary Fig.15 and Supplementary Table 5). Also, CAStotal was able to identify patients for 356 
both DCIS (Supplementary Fig.16A and B, Supplementary Table 8Ai and 8Bii) and invasive recurrence 357 
even after adjusting for potentially confounding effects of factors like age, grade, and RT 358 
(Supplementary Fig. 16C and D, Supplementary Table 8AiI and 8Bii) in both DC and VC. 359 
(clinicopathological characteristics summarized in Supplementary Table 6 and 7). 360 
Further, in both the DC and VC, the 10-year estimated risk of LR increased continuously as the CAS 361 
increased (Supplementary Fig.17). Next, we determined if our survival model had high predictive 362 
accuracy using the Harrell’s concordance index. The higher the concordance index, the better the 363 
survival model discriminates between patients who experienced LR versus those who remained LR-364 
free. The results indicated that any patient with a poorer/shorter RFS had a 72.6% probability of being 365 
in the high CAStotal group. Also, we created a 2x2 confusion matrix performance metrics to show the 366 
accuracy of CAS to predict 10-year LR. To do so, we calculated the sensitivity (Sn), specificity (Sp), 367 
positive predictive value (PPV), negative predictive value (NPV) and accuracy (Acc) of CAS and odds 368 
ratio (OR which represents the increase in odds of a patient in a high-risk group developing recurrence 369 
relative to a patient in a low-risk group), for both cohorts to compare the performance of CAS with that 370 
of the traditional clinicopathological variables (those used in the Cox regression analysis). As presented 371 
in the tables below, our CAStotal yielded an accuracy (or Acc) of 0.60, sensitivity of 0.85, specificity of 372 
0.53, PPV of 0.32, NPV of 0.93, and OR of 6.8 in the DC (Supplementary Table 9). We noticed that  the 373 
CAStotal produced a lower accuracy and specificity compared to comedo necrosis (0.71). However, 374 
comparison of the Sp, PPV, NPV, and OR performance metrics showed the overall superiority of 375 
CAStotal, in both cohorts, when compared to the clinicopathologic variables.  376 
Thus, these results collectively show that CAS can robustly predict 10-year LR risk for DCIS patients 377 
from two different cohorts. 378 
 379 
4. CAS can identify patients who could benefit from radiotherapy 380 
 381 
In the DC, CAStotal stratified DCIS patients treated with surgery (mastectomy/BCS) or BCS alone 382 
(Supplementary Fig. 18B and 18C) into subgroups with high and low LR risks with greater significance 383 
relative to patients treated with surgery (mastectomy/BCS) and post-operative RT (Supplementary Fig. 384 
18A) (HR=11.6, p<0.0001 for surgery alone; HR=17.05, p=0.0005 for BCS alone, and HR=2.4, 385 
p=0.3589 for surgery + RT). Similarly, in  the VC, CAS stratified DCIS patients treated with surgery only 386 
(Supplementary Fig 19A and 19B) into subgroups with high and low LR risks with higher significance 387 
compared to patients treated with surgery (mastectomy or BCS) and post-operative adjuvant RT 388 
(surgery+RT) (HR=3.97, p=0.049 for surgery alone and HR=1.4, p=0.109 for surgery+RT). These data 389 
suggest that CAStotal can identify LR patients who might benefit from adjuvant RT. In addition, we 390 
observed that DCIS patients who recurred as IBC exhibited higher CAStotal (p=0.07) compared to the 391 
patients who recurred as DCIS (Supplementary Fig. 20) in the DC.  392 
 393 
We next evaluated the clinical significance of CAS by examining the associations of CAS with 394 
traditionally-employed clinicopathological variables i.e., age, grade, tumor size, comedo necrosis, and 395 
RT (Supplementary Figs. 21 and 22). Our data shows that CAStotal provides clinically-relevant 396 
prognostic information over and beyond what is provided by current clinicopathologic parameters alone. 397 
Given that high CA is associated with more aggressive disease phenotypes, we not only observed the 398 
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association of high CAStotal with higher recurrence rates (RR), but also found that CAStotal segments 399 
patient subgroups more deeply than traditional clinicopathologic parameters (see RR forest plot in 400 
Supplementary Fig. 16A). For example, the RR forest plot (Supplementary Fig. 23A) for high grade 401 
DCIS patients in the DC showed that patients with comedo necrosis (red), are at high risk of recurrence 402 
(0.59) compared to the overall RR for patients (0.33), regardless of the CAS of their tumors. When we 403 
further stratified these DCIS patients with comedo necrosis into high (green) and low (blue) CAS 404 
groups, we observed that the RR for the high CAS group (green) was 0.83 and RR for the low CAS 405 
subgroup (blue) was 0.10. Similar results were observed for VC (see RR forest plot in Supplementary 406 
Fig. 23B). Thus, CAS was able to more deeply segment the patients with comedo necrosis into high 407 
and low risk LR groups. Similar trends were evident for tumor size, RT, and age.  408 
 409 
5. CAS stratification of DCIS patients into LR and LR-free groups is superior to that afforded by 410 
the Van Nuys Prognostic Index (VNPI) 411 
 412 
The widely used VNPI is based on patients’ age at diagnosis, tumor size, resection margin width and 413 
tumor grade. To test the performance of this index in our (DC and VC combined) cohort, we calculated 414 
VNPI based on scoring methods described in the literature. Each of the factors was assigned a score 415 
between 1-3, and the sum of scores for the four parameters (i.e., the final VNPI score) was used to 416 
stratify patients into high, low and intermediate risk groups for LR, employing the binary cutoff score of 417 
³8. Next, we compared the performance of VNPI and CAStotal in cases from the DC and VC (n=164) 418 
(Fig. 4A and 4B) using univariate and Kaplan Meier survival analyses. We found that higher VNPI was 419 
not significantly associated with poorer RFS and VNPI did not significantly stratify patients as high and 420 
low risk of LR subgroups. By contrast, CAStotal stratified DC and VC patients into subgroups of high 421 
and low risk of LR with greater significance and HRs (CAStotal HR=5.6 vs. VNPI HR=0.70) 422 
(Supplementary Table 10). Multivariable analyses adjusted for other potentially confounding factors, 423 
such as tumor size, presence of comedo necrosis, age, and RT along with VNPI and CAS, revealed 424 
that CAStotal showed the highest association with RFS, with a HR=6.86 (Supplementary Table 11). 425 
These findings compellingly suggest that the CAS stratification of DCIS patients is superior to that of 426 
the traditional VNPI index.  427 
 428 
Discussion  429 
 430 
DCIS exhibits considerable inter-patient heterogeneity and has a poorly understood natural history. A 431 
lack of accurate models for prediction of risk of LR results in over- and under-treatment, complicated by 432 
the variable prognostic evidence of patient age, tumor margins, DCIS grade, and size. CA is a hallmark 433 
of cancers and is observable in >80% of breast tumors including pre-invasive lesions, and is associated 434 
with high grade in DCIS and IBC (18,19). Amplified centrosomes are present in premalignant cells and 435 
increase as the disease progresses to dysplasia, highlighting the potential involvement of CA in 436 
neoplastic transformation and progression (25).  437 
 438 
Our laboratory has previously shown that (a) high levels of CA are associated with poor progression-439 
free survival in invasive breast tumors, and (b) CA is higher in the aggressive TNBC subtype compared 440 
to grade-matched non-TNBCs (26,27).  This notion was further validated by analysis of the CA20 gene 441 
score, which is based on genes associated with CA (28). Recent studies have reported that higher CA 442 
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induces high-grade features in BCs; thus, CA has been associated with tumor evolution (29). Although 443 
studies have reported that BCs exhibit structurally amplified centrosomes, they have not yet established 444 
the prognostic value of this structural CA (30). This may be due, in part, to the 2D (i.e., cross-sectional) 445 
approaches used in these studies, which have limitations to accurately capture the 3D size of the 446 
centrosome. Moreso, most studies (31) examining CA in BCs have not rigorously evaluated 447 
confounding effects of other clinicopathologic variables on the prognostic value of CA.  448 
 449 
Our new semi-automated methodology uses quantitative centrosomal phenotyping and an algorithm to 450 
measure both numerical and structural centrosomal aberrations in DCIS tumors. For each sample, a 451 
continuous CAS was computed that categorized patients as having a high or low 10-year risk of LR. 452 
Findings from our retrospective study, which involved two large, well-characterized cohorts (DC and 453 
VC) of DCIS cases, showed that patients with LR within 10 years exhibited higher CAStotal relative to 454 
LR-free patients. Our study is the first to show that organellar-level differences distinguish DCIS 455 
patients with LR from LR-free patients, and that high levels of both numerical and structural CA are 456 
associated with increased 10-year risk of LR in DCIS patients. Our results suggest that aberrant 457 
centrosomal homeostasis in DCIS drives pathophysiological alterations that potentially facilitate disease 458 
progression through CIN-dependent as well as CIN-independent mechanisms. While CA may drive ITH 459 
through CIN, an increased centrosome complement may, via modulation of the microtubule 460 
cytoskeleton, enhance directional migration and invasion of malignant cells and thus enhance the risk 461 
of LR in the longer term (32). We have demonstrated that CAStotal is significantly and independently 462 
associated with poor RFS, and upon inclusion of both CAStotal and VNPI into multivariable models, we 463 
found that CAStotal outperforms VNPI in predicting LR. CAStotal predicts the 10-year risk of LR with 464 
higher concordance than VNPI. In DCIS patient subsets, defined based on their clinical and 465 
histopathological parameters, stratification by CAStotal prognostically augmented several 466 
clinicopathologic parameters in determining rate of recurrence. Among subsets of DCIS patients treated 467 
with BCS or those receiving additional adjuvant RT, CAStotal identified patients with high risk of LR. 468 
Thus, CAStotal can be used as a clinical tool to identify patients who can be safely treated with 469 
BCS/mastectomy alone, and those who will benefit from the inclusion of RT. Our centrosomal profiling 470 
methodology, which dichotomizes DCIS patients into high- and low- risk categories, enables clear 471 
go/no-go therapeutic decision making, and can substantially augment individualized management of 472 
DCIS based upon risk conferred by the patient’s centrosomal complement. 473 
 474 
CAS, as the linear expression of the severity and frequency of numerical and structural CA, may serve 475 
as an indirect measure of ITH in DCIS. Our study, the first to robustly quantify CA in both pure and 476 
mixed DCIS samples, has contributed evidence supporting a model of CA-driven DCIS progression into 477 
IBC. These findings concur with previous studies wherein we, and others, observed that TNBC, the 478 
most aggressive subtype of BC, exhibits highest CA among all BC subtypes (26,29). Centrosome 479 
profiling can complement clinicopathologic and genomic evaluation to provide a comprehensive portrait 480 
of disease status. An exciting avenue for future research is to profile CA in all the stages of tumor 481 
progression starting from atypical hyperplasia to invasive and metastatic disease to evaluate if CA can 482 
function as a biomarker for tumor evolution.  483 
 484 
The commercially available Oncotype Dx DCIS score is applicable mainly to cases with resection 485 
margins of at least 3 mm and low/intermediate-grade DCIS measuring ≤2.5 cm, or in high-grade DCIS 486 
12 
of ≤1 cm, as this is the set of patients from the ECOG 5194 study upon which the test was initially 487 
clinically validated (11). By contrast, our quantitative centrosomal phenotyping methodology is more 488 
broadly applicable and could be refined for other cancer types with rampant CA. The gene signature 489 
that comprises the basis of the Oncotype DCIS Score consists mainly of proliferation-related genes. CA 490 
is a phenotypic biomarker that serves as a readout of hundreds of deregulated signaling pathways that 491 
culminate in numerical and/or structural CA, including dysregulated proliferation-related signaling 492 
cascades. Thus, our methodology captures prognostic information from a broader swath of biological 493 
pathways that are deregulated in and drive the biology of DCIS. CAS-based risk profiling of core 494 
biopsies may reduce the number of re-excisions even in the event of close/positive margins. 495 
 496 
 However, our study has a few limitations. There are imbalances in the number of patients in different 497 
subgroups, in the DC and the VC of the study, which has resulted in better performance of CAS (higher 498 
HR) in the DC. While the DC has more high-grade patients, the VC has a balanced number of high, 499 
intermediate, and low-grade patients. High-grade patients tend to present with invasive recurrence. A 500 
higher number of patients recurred as invasive in the DC and patients with invasive recurrence 501 
exhibited higher CAS when compared to patients who recurred as DCIS in DC. Whereas, in VC due to 502 
more balanced numbers of high, intermediate, and low-grade patients, no such variation in the type of 503 
LR was observed. Furthermore, lack of receptor status in some cases precluded study of the 504 
confounding effect of receptors in this dataset. The study cohort did not include any patients treated 505 
with endocrine therapy. These limitations in the DC and VC perhaps lead to the slightly different 506 
performance of CAS among the two cohorts. Validation studies in external cohorts and mechanistic 507 
studies to understand the role of CA- associated proteins in DCIS progression model are warranted. 508 
 509 
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Table 1: Descriptive statistics of clinicopathological characteristics for pure DCIS based on the 604 
recurrence status in the (A) DC and (B) VC. The 𝜒"p-values were used to determine if the differences 605 




Table 2: Univariate and multivariate Cox proportional regression analysis for the risk of LR in DCIS 609 
treated with BCS or mastectomy comparing the influence of common clinicopathological variables 610 
relative to CAStotal in (A) DC and (B) VC.   611 
 612 
Figure Legends  613 
 614 
Figure 1. Schematic depicting semi-automated workflow to quantify CA in clinical samples. A 615 
description of terms used in the algorithm is provided in the Methods section. (A) Centrosomes in 616 
breast tissues (normal, DCIS or IBC) were categorized into individually distinguishable centrosomes 617 
(iCTRs) and megacentrosomes (mCTRs). iCTRs were defined as centrosomes that stain positive for γ-618 
17 
tubulin and whose volumes lie within the range of centrosome volumes found in normal breast tissue 619 
stained for γ-tubulin. (B) mCTRs were defined as centrosomes in a neoplastic region that stain positive 620 
for γ-tubulin and whose volume is greater than the upper limit of the centrosome volume range found in 621 
corresponding normal tissue immunostained for γ-tubulin. Thus, mCTRs are centrosomes with 622 
aberrantly large volumes and are considered to represent structurally amplified centrosomes. 623 
 624 
Figure 2: DCIS cases in the DC with ipsilateral recurrence exhibit higher CAS than recurrence-free 625 
cases. (A) Representative H&E images (20x magnification) of the ducts from DCIS cases with and 626 
without LR. Black boxes represent the area magnified in panel B. (B) Confocal micrographs showing 627 
numerical (green arrows) and structural (yellow arrows) CA in DCIS with or without recurrence. Tissue 628 
sections were immunostained for centrosomes (γ-tubulin, red) and nuclei (Hoechst, blue). Scale bar 629 
(white), 20μm. Beeswarm box plots showing Wilcoxon ranks for pure DCIS cases with LR (n=28) and 630 
without LR (n=105). (C) CASi (D) CASm (E) CAStotal. p<0.05 was considered statistically significant. 631 
Beeswarm box plots showing Wilcoxon ranks for pure DCIS cases with LR (n=24) and LR-free cases 632 
(n=95) in VC (F) CASi, (G) CASm, and (H) CAStotal. p<0.05 was considered statistically significant.  633 
 634 
Figure 3: In the DC and VC, higher CAS is associated with poorer RFS. Kaplan Meier survival curves 635 
representing the RFS of patients in the DC stratified into (A) CASi high and low groups, (B) CASm high 636 
and low groups, (C) CAStotal high and low groups. Kaplan Meier curves representing the RFS of DCIS 637 
patients in the VC stratified into (D) CASi high and low groups, (E) CASm high and low groups, and (F) 638 
CAStotal high and low groups. N: total number of patients in each group; R: number of patients who 639 
developed LR; % represents the percentage/proportion of patients with LR out of the total number of 640 
patients with LR in both groups combined.  641 
 642 
Figure 4: Comparison of the stratification of DCIS patients by CAStotal and Van Nuys Prognostic Index 643 
(VNPI). Kaplan Meier survival curves representing the RFS of DCIS patients (n=164) stratified by (A) 644 
CAStotal, and (B) VNPI. N: total number of patients in each group; R: number of patients who showed 645 
LR; %: percentage/proportion of patients with LR out of the total number of patients with LR in the DC 646 




Supplementary Materials and Methods 
 
 
Supplementary Figure 1: Kaplan Meier survival curves representing the RFS of patients in the DC stratified 
into “CAS total” high and low groups in a cohort of 50 patients.   
 
 
Supplementary Figure 2: REMARK diagram describing the flow of patients through the study, including the 







Supplementary Figure 3: Representative immunographs of normal and normal adjacent breast tissue sections 
for centrosomes. (A) Representative H&E images of the ducts of the normal and normal adjacent breast tissue 
sections. (Images were captured at 20x magnification). (B) Confocal micrographs showing numerical and 
structural CA in normal adjacent breast tissue sections. 
 
 
Supplementary Figure 4: Schematic depicting the high and low severity and frequency of (A) numerical 
centrosome amplification and (B) structural centrosome amplification.  
Quantitation of numerical CA: 
For CASi, equation 1 represents how an aggregate value reflecting both frequency and severity of numerical 
CA was derived for each sample: 	
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Rth is the highest number of centrosomes present in a normal breast cell, i.e., 2. Ni is the number of iCTRs in a 
cell that contains more than 2 iCTRs; Thus, (Ni- Rth) indicates the number of excess centrosomes present in a 
cell with numerical CA; R is the range of values for number of centrosomes present in a normal cell, which is 2 
here; pi is the percentage of cells with >2 iCTRs;  ßi is a scaling factor to ensure that both CASi (numerical) and 
CASm (structural) are assigned equal weight in the formula  for CAStotal; N is the total number of cells analyzed 
in the sample; Ni depicts the average number of cells with numerical CA.  
  
The “severity” component of CASi, (i.e., 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 NDHOPQR
P
S	quantifies how “severe” the numerical CA is [i.e., the 
extent to which the numerical CA exceeds the baseline value of 2 in cells that carry three or more iCTRs (i.e., 
Ni >2)] (Supplementary Fig. 4Ai and 4ii).  Therefore, cancer cells with 1 or 2 iCTRs do not contribute to this 
component.  Since cells with larger numbers of iCTRs represent severe numerical CA, a linear measurement 
was implemented to provide a measure of the number of iCTRs (above the baseline value of 2) in a given cell 
by computing the score (Ni - 2) for each cell. Finally, an average of all these scores is determined.  The 
“frequency” component of the CASi score (i.e., pi/ßi) provides the scaled frequency of numerical CA in the 
sample (Supplementary Fig. 4Aiii and iv). The value of CASi scaling factor 𝛽. used here is 0.1 for breast tissue. 
 
Quantitation of structural CA: 
Equation 2 for CASm represents how an aggregate value reflecting both frequency and severity of structural 
CA is derived for the sample:  
	



















𝑉.Vis the volume of the 𝑚12 mCTR in the 𝑖12 nucleus; 
𝑝Vis the percentage of cells with mCTRs; where a mCTR is defined as a centrosome whose volume exceeds 
the 𝑉12 critical for that tissue; 𝑉12 critical for a given tissue is the maximum volume of a normal centrosome in 
that tissue, which is 0.735 µm3 for breast tissue; 𝛽Vis a scaling factor used to ensure that both CASi and CASm 
contribute equally towardsCAStotal. Value of 𝛽Vused here is 0.148.  𝜎X.V is the standard deviation of the volume 
of mCTRs. 
For each mCTR, a z-score was computed based on the formula below, reflecting the extent to which the volume 
of that mCTR exceeded the maximal normal value (i.e., the value for 𝑉.V − 𝑉12critical is computed) relative to 





Next, this value was multiplied by the number of mCTRs per nucleus. Finally, all values were averaged to obtain 
the severity score for structural CA (Supplementary Fig. 4Bi and ii). The frequency component of CASm has 
essentially the same overall mathematical formula as the corresponding term in the CASi component 





Supplementary Figure 5: Graphical checks of the proportional hazards assumption: Scaled Schoenfeld 







Supplementary Figure 6: Histograms representing the distribution of (A) age in DC, (B) tumor size in DC, (C) 




Supplementary Figure 7: Kaplan Meier survival curves representing the RFS of patients in the DC and VC 
combined cohort (n=252) stratified into high and low groups based on (A) age, (B) grade, (C) comedo necrosis, 
and (D) radiotherapy. n: total number of patients in each group; R: number of patients who developed LR; % 




Supplementary Figure 8: DCIS cases in the DC with LR exhibit higher frequency and severity of both numerical 
and structural CA: Beeswarm box plots showing Wilcoxon ranks for different CASs in pure DCIS cases with, 
LR(n=28) and without LR (n=105) in DC (A) CASi severity, (B) CASi frequency, C) CASm severity, (D) CASm 
frequency. Beeswarm box plots showing Wilcoxon ranks for different CASs in pure DCIS cases with with LR 
(n=24) and without LR (n=95) in VC (E) CASi severity, (F) CASi frequency, (G) CASm severity, (H) CASm 





Supplementary Table 1: Means scores and p-values of CASi, CASm and CAStotal in recurrence and 




Supplementary Figure 9: Representative confocal micrographs of DCIS tissue sections from VC 




Supplementary Figure 10: Grade-matched DCIS cases with LR exhibit higher CAS than grade-matched cases 
without LR: (A) Beeswarm box plots showing CAStotal Wilcoxon ranks for high-grade DCIS with LR (n=21) and 
without LR (n=97) in DC. (Bi) Beeswarm box plots showing CAStotal Wilcoxon ranks for low-grade pure DCIS 
(n=23) cases with LR (n=3) and without LR (n=20) in VC. (Bii) Beeswarm box plots showing CAStotal Wilcoxon 
8 ranks for intermediate-grade pure DCIS (n=37) cases with LR (n=9) and without LR (n=28) in VC, and (Biii) 
Beeswarm box plots showing CAStotal Wilcoxon ranks for high-grade pure DCIS (n=59) cases with LR (n=12) 
and without LR (n=47) in VC. p<0.05 was considered statistically significant 
 
 
Supplementary Figure 11: Recurrent DCIS cases treated with BCS in the DC exhibit higher CAS than 
recurrence-free cases: Beeswarm plots showing Wilcoxon ranks for pure DCIS cases with LR (n=27) and without 
LR (n=91) (A) CASi, (B) CASm, and (C) CAStotal. p<0.05 was considered statistically significant.  
 
 
Supplementary Figure 12: Representative confocal micrographs of DCIS tissue sections immunolabeled for 




Groups p-value Hazard Ratio 
CASi severity 0.120 2.77 
CASi frequency <0.001 4.77 
CASm severity 0.006 5.40 
CASm frequency 0.072 2.44 
Supplementary Table 2: Hazard Ratio and p value for the severity and frequency of CASi and CASm in DC. 
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Supplementary Figure 13: Higher severity and frequency of numerical and structural CA are associated with 
poor RFS in the DC of DCIS cases:  Kaplan-Meier survival curves representing the RFS of patients in: (A) high 
and low groups based on the severity component of numerical CA, (B) high and low groups based on the 
frequency component of numerical CA, (C) high and low groups based on the severity component of structural 
CA, (D) high and low groups based on the frequency component of structural CA. N: total number of patients in 
each group; R: number of patients who showed LR. %: percentage/proportion of patients with LR out of the total 
number of patients with LR in both groups combined. 
 
Supplementary Figure 14: Higher CAS is associated with poorer RFS for DCIS patients treated with BCS in 
the DC: Kaplan Meier survival curves representing the RFS of patients in the DC stratified into: (A) CASi high 
and low groups, (B) CASm high and low groups, (C) CAStotal high and low groups. N: total number of patients 
in each group; R: number of patients who developed LR; % represents the percentage/proportion of patients 




Supplementary Table 3: Univariate Cox proportional regression analysis for the risk of LR in DCIS treated with 
BCS or mastectomy comparing the influence of common clinicopathological variables relative to CASi and CASm 
in DC and VC.   
 
 
11 Supplementary Table 4: Multivariate Cox proportional regression analysis for the risk of LR in DCIS treated 
with BCS or mastectomy comparing the influence of common clinicopathological variables relative to CASi and 




Supplementary Table 5: Table representing the Hazard Ratios from univariate and multivariate bootstrap 
analysis for CAStotal (high vs low).  
 
 
Supplementary Figure 15: Fitted normal and kernel density curves on the histogram are estimated based on 
the bootstrap sample mean and standard deviation. They show that 1000 hazard ratios are nearly normally 





Supplementary Table 6:  Descriptive statistics of clinicopathological characteristics for pure DCIS based on the 
recurrence status in the DC (A) where recurrence was in DCIS form and (B) where recurrence was in invasive 




Supplementary Table 7: Descriptive statistics of clinicopathological characteristics for pure DCIS based on the 
recurrence status in the VC (A) where recurrence was in DCIS form and (B) where recurrence was in invasive 
form. The 𝜒J	p-values were used to determine if the differences in proportions were statistically significant. 
14 
 
Supplementary Table 8: Multivariate Cox proportional regression analysis for the risk of LR in DCIS treated 
with BCS or mastectomy comparing the influence of common clinicopathological variables and receptor status 
relative to CAStotal in (A) DC where recurrence was in DCIS form , (Aii) DC where recurrence was in invasive 
form (Bi) VC where recurrence was in DCIS form (Bii) VC where recurrence was in invasive form. 
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Supplementary Table 9: The 2x2 confusion matrix and performance metrics for CAStotal and common 
clinicopathological variables in the (A) DC and (B) VC. For each variable, the positive condition was recurrence 





Supplementary Figure 16: In DC and VC, higher CAS is associated with poorer RFS. Kaplan Meier survival 
curves representing the RFS of patients in the DC stratified into CAStotal high and low groups in, (A) DC where 
recurrence was in DCIS form , (B) DC where recurrence was in invasive form (C) VC where recurrence was in 
DCIS form (D) VC where recurrence was in invasive form. N: total number of patients in each group; R: number 
of percentage/proportion of patients with LR out of the total number of patients with LR in both groups combined. 
%: percentage/proportion of patients with LR of the total number of patients with LR in both groups combined. 
p<0.05 is considered significant. 
 
 
Supplementary Figure 17: Estimated 10-year risk of developing a LR as a continuous function using CAS 
based on a Cox proportional hazards model, including 95% confidence intervals demonstrating the level of 
precision in the estimates.  
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Supplementary Figure 18: Higher CAS is associated with poor RFS for DCIS patients treated with BCS alone:  
Kaplan Meier survival curves representing RFS of the DCIS patient subgroups stratified based on high vs. low 
CAStotal: (A) DCIS patients treated with surgery and adjuvant RT (mastectomy/BCS+RT), (B) DCIS patients 
treated with surgery alone (mastectomy/BCS), (C) DCIS patients treated with BCS alone. N: total number of 
patients in each group; R: number of patients who showed LR; %: percentage/proportion of the patients with LR 
of the total number of patients with LR in both groups combined. 
 
Supplementary Figure 19. Higher CAS is associated with poor RFS for DCIS patients in the VC treated with 
surgery alone: Kaplan Meier survival curves representing the RFS of the DCIS patient subgroups stratified based 
on high vs. low CAStotal (CAStotal cutpoint used was the same as in the DC): (A) DCIS patients treated with 
surgery (BCS/mastectomy) and adjuvant RT (surgery+RT), (B) DCIS patients treated with surgery alone. N: total 
number of patients in each group; R: number of patients who showed LR; %: percentage/proportion of patients 







Supplementary Figure 21: Distribution of the CAStotal according to clinical and pathologic characteristics, 
including scatter plots and the frequency in each prespecified risk group for the DC. Distribution of CAStotal 
according to (A) age, (B) grade, (C) tumor size, (D) comedo necrosis, and (E)RT. Blue: number and percentage 
of patients in the low-CAStotal subgroup; Red: Number and percentage of patients in the high-CAStotal 
subgroup. 
 
Supplementary Figure 20: DCIS cases who 
recurred as IBC exhibited higher CAStotal 
compared to the patients who recurred as DCIS. 
Beeswarm Box plots showing CAStotal Wilcoxon 
ranks for pure DCIS  who recurred as IBC  (n=18) 





Supplementary Figure 22: Distribution of the CAStotal according to clinical and pathologic characteristics, 
including scatter plots and the frequency in each prespecified risk group for VC. Distribution of CAStotal 










Supplementary Figure 23: (A) CAStotal allows deeper stratification of patient subgroups than traditional 
clinicopathologic parameters alone in the HG DCIS patient subgroups from the DC. Forest plot representing 
estimates of 10-year RRs (with 95% CIs) within HG DCIS patient subgroups (from the DC) defined by clinical 
parameters alone, or within the CAStotal high and low risk subpopulations within these subgroups. The CAStotal 
cutpoint used here was that used for the whole DC patient population (133 patients) and not the optimal cutpoint 
for the patient subgroup. The black box represents the overall RR observed for the DCIS patients in the DC. The 
red boxes represents the RR observed among the patients in the specific subgroup defined by the clinical 
parameter  (regardless of their  CAStotal). The green boxes represents the RR in the high CAStotal sub-
population and the blue boxes represents the RR in the low CAStotal sub-population within each subgroup. (B) 
CAStotal enables deeper stratification of patient subgroups than traditional clinicopathologic parameters alone 
in the VC. Forest plot representing estimates of 10-year RRs (with 95% CIs) within DCIS patient subgroups (from 
VC) defined by clinical parameters alone, or within the CAStotal high- and low-risk subpopulations within these 
subgroups. The CAStotal cutpoint used here was the cutpoint used for the entire DC patient population (119 
21 patients) and not the optimal cutpoint for the patient subgroup. The black box represents the overall RR observed 
for the DCIS patients in the DC. The red boxes represents the RR observed for the patients in the specific 
subgroup defined by the clinical parameter (and regardless of their CAStotal). The green boxes represent the 
RRs in the high CAStotal sub-population, and the blue box represent the RRs in the low CAStotal sub-population 












Table 10: Univariate analyses evaluating the impact of CAStotal and VNPI on the RFS of DCIS patients treated 












Table 11: Multivariate analyses evaluating the impact of CAStotal, VNPI and other clinicopathological 
parameters on the RFS of DCIS patients treated with BCS. 
 
 
 
